Revenue ($USD) : $6,939,900,000
R&D spend : $406,000,000.00
Employees : 18,000
Fiscal year end : 12/31/22
CEO : Ivan Tornos

Zimmer Biomet is pushing innovation and better execution as elective procedures at health providers recover from the pandemic and younger people opt for orthopedic procedures.

During ZB’s Q2 2023 earnings call, former CEO Bryan Hanson (who's joining 3M's healthcare spinoff as CEO) noted that Zimmer Biomet has 40 planned product launches between this year and the end of 2025, the majority in 4%-plus growth markets. For example, ZB officials said they plan a full market release of their Persona IQ smart knee implant by Q1 2024, and they still expect to be first-to-market with a robotic shoulder surgery application with their Rosa platform.

Zimmer Biomet continues to enhance its ZBEdge Dynamic Intelligence platform for hip and knee surgeries. In March, it announced a definitive agreement to acquire Ossis, a maker of personalized 3D-printed implants. –CN